RxDoctor Payments Data

Patrick Moore, DPM

Podiatrist · Kearney, NENPI 1558321505

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (40.2%), education and food and beverage — rather than concentrated in one kind of arrangement. Conetic Solutions, Inc. accounts for 77.3% of it on its own, with 10 other manufacturers making up the rest.

$3,093in general payments, 2019–2025

Across 25 payments — averaging $123.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Conetic Solutions, Inc.$2K
  • Arthrex$293
  • Organogenesis Inc.$108
  • Prism Medical$67
  • Abbott$61
  • Paragon 28, Inc.$54
  • plus $121 from 5 others

What the payments were for

  • Travel & lodging$1,24340%
  • Food & beverage$65021%
  • Education$1,20039%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,093 in reported general payments places this provider in the 55th percentile of 29 podiatrist providers in Nebraska.

See all podiatrist providers in Nebraska

Medicare billing

Part B allowed, 2024
$99,645
Medicare patients
656
Services billed
2,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha22$371

Paid to pharmacies, not to this prescriber.

Other podiatrist in Kearney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →